Investor Presentaiton slide image

Investor Presentaiton

Vaccines: Robust growth driven by GARDASIL • GARDASIL sales of $2.6B increased 16% year-over-year driven by strong demand, particularly in China - In the U.S., sales decreased due to the GARDASIL. [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] GARDASIL.9 [Human Papillomavirus 9-valent Vaccine, Recombinant] timing of CDC purchases $2.3B +20% $2.6B +16% • Strong uptake of the pediatric indication of VAXNEUVANCE in the U.S. and $2.0B +63% launches in key European markets Growth rates exclude the impact of foreign exchange. 3Q21 3Q22 3Q23 MERCK 13
View entire presentation